Welcome - Mesa Day Two

ARM’s Role in the Sector

Janet Lambert, CEO
October 3, 2019
About ARM

• **International advocacy organization**
  • Dedicated to realizing the promise of safe and effective regenerative medicines for patients around the world
  • Cell and gene therapy, tissue engineering

• **340+ members**
  • Small and large companies, non-profit research institutions, patient organizations, and other sector stakeholders
  • Across 25 countries

• **Priorities:**
  • Clear, predictable, and harmonized **regulatory** pathways
  • Enabling market access and value-based **reimbursement** policies
  • Addressing industrialization and **manufacturing** hurdles
  • Conducting key stakeholder outreach, **communication**, and education
  • Facilitating sustainable access to **capital**
Market Access

Drive Adoption of New Payment Models and Value-based Reimbursement

• Lobby in support of legislation in the U.S.
  • Held 90+ meetings with congressional offices during ARM Fly-In
  • Organized Congressional educational briefings on gene therapy, market access
  • Key Provisions included in Senate Finance Committee-approved bill
• Testified at the CMS Town Hall, filed comments, met with CMS seeking improvements in CAR-T coverage and reimbursement
  • NTAP increased from 50% to 65%
  • National Coverage Decision finalized
  • CMS will consider CAR-T DRG for FY 2021
• Analytical Work
  • Summer ’19: Status of market access for ATMPs in key European countries, including barriers to and recommendations for timely patient access
  • Fall ’19: Roadmap for Managed Care Access, w/NAMCP
  • Fall ’19: Potential Cost Saving of Cell And Gene Therapies For The Next Decade
Regulatory Pathways

Clear, Predictable, Effective, Harmonized Regulation of Regenerative Medicines

- Regular engagement with the FDA & EMA; invited to ICMRA meeting in October
- Topics: disease specific guidances, CMC requirements, registries, good clinical practice, trial design, European repository of regulatory requirements, GMO harmonization, ARM’s analysis of the discrepancies in US and EU regulations for ATMPs, etc
Manufacturing Barriers

- Member workshop on comparability in cell & gene therapy development, with USP & global regulators
- *In Vivo* publication on manufacturing challenges in cell and gene therapy in June, and co-hosted a follow-up webinar in September
- Finalizing a comprehensive framework document -- A-Gene -- covering development, manufacture, regulatory submission, and lifecycle of gene therapies
  - Expected release in early 2020
  - Content is currently being drafted for A-Cell, a similar project focusing on cell therapies

A-Gene participants include:
Standards Coordinating Body Update

The SCB, co-founded by ARM in 2016, is making major advances in standards that benefit the growth of the entire regenerative medicine field

Connecting the Regenerative Medicine Community to the Standards Development Process

• As an independent, fully-staffed, 501(c )(3) organization, SCB works to coordinate standards activities, engage experts, and educate the regenerative medicine community.

• Drives FDA-funded standards activities (third FDA contract recently executed), collaborates with NIST

• Fifteen standards advancement projects underway
  • Comprehensive landscape reports
  • Industry education and workshops
  • Involved in five ISO standards this year

Connect with an SCB leader here at Mesa19!

FOR MORE INFORMATION VISIT www.standardscoordinatingbody.org OR CONTACT preczek@regenmedscb.org
• Elevated Industry voice in the gene editing international dialogue by releasing a Therapeutic Developers’ Statement of Principles on Human Genome Editing
  • Signed by 14 preeminent companies active in developing gene-edited therapies.
    • Audentes, bluebird bio, BlueRock, Caribou Bio, Casebia, CRISPR, Editas, Homology, Intellia, LogicBio, Precision, Sangamo, Tmunity, Pfizer
  • Asserted that the clinical use of germline gene editing is currently inappropriate
• Still accepting signatures from ARM member companies
• Presented at an August 27 meeting of the WHO’s expert advisory panel on human genome editing in Geneva; Engaged with NAS gene editing panel
Reports & Data Resources

• Sector reports, providing clinical and financial data as well as commentary on the sector
  
  o Global data
  o Regional data
  o Indication-specific reports

• Sortable, searchable databases:
  
  o Expedited Approval Designations Database
  o Anticipated Clinical Data Readouts & Trial Milestones

• Available: www.alliancerm.org
News You Can Use

**Sector Newsletter**
Publicly available sector newsletter distributed to nearly 12,000 life science professionals each week.

- Recent financings & business deals;
- New clinical data & milestones;
- Scientific advancements;
- Policy news and updates; and
- Job opportunities with ARM members

**Member Briefing**
Members-only monthly activity briefing, launched 2018.

- Recent and ongoing ARM initiatives;
- Exclusive member memos and publications;
- Opportunities for engagement;
- Notable sector news and events

To sign up: Visit [www.alliancerm.org](http://www.alliancerm.org) or contact Kaitlyn Donaldson at kdonaldson@alliancerm.org
ARM Foundation for Cell & Gene Medicine

Launched by ARM in 2018

The ARM Foundation serves as the educational and information catalyst on issues fundamental to making gene and cell therapies, tissue-engineered products and other regenerative medicine treatments available to patients.

By examining, quantifying, clarifying and informing stakeholders of the clinical and societal benefits of these therapies, as well as convening discussions to raise awareness about the sector’s progress, challenges and results, the Foundation accelerates patient access to safe, efficacious and potentially curative therapies.

Fifteen Minute Overview of the Foundation’s Work: Friday 9:00am, BlueRock Ballroom
# ARM Board of Directors

## Officers:

**Matthew Patterson**  
Chairman  
Chairman and CEO  
Audientes Therapeutics

**Emile Nuwaysir, Ph.D.**  
Vice-Chairman  
President and CEO  
BlueRock Therapeutics

**Amy Butler, Ph.D.**  
Secretary  
VP and GM Cell Biology  
Thermo Fisher Scientific

**Jeffrey Walsh, MBA**  
Treasurer  
Chief Strategy Officer  
bluebird bio

## Board of Directors:

**Zami Aberman**  
Chairman and Co-CEO  
Pluristem Therapeutics

**Usman 'Oz' Azam, M.D.**  
President and CEO  
Tmunity Therapeutics

**Ronald Bartek**  
Co-Founder and President  
Friedreich’s Ataxia Research Alliance

**Joanne Beck**  
Executive Vice President  
Global Pharmaceutical Development & Operations  
Celgene Corporation

**Flagg Flanagan**  
Chairman and Chief Executive Officer  
DiscGenics

**Miguel Forte, M.D., Ph.D.**  
CEO  
Zelluna Immunotherapy

**Kristen Harrington-Smith, MBA**  
VP and Head, CAR-T US  
Novartis Oncology

**Michael Hunt, ACA**  
CFO  
ReNeuron

**Paul Laikind, Ph.D.**  
President and CEO  
ViaCyte

**Bruce Levine, Ph.D.**  
Barbara and Edward Netter Professor in Cancer Gene Therapy, and Founding Director, Clinical Cell and Vaccine Production Facility, Department of Pathology and Laboratory Medicine, Abramson Cancer Center  
Perelman School of Medicine, University of Pennsylvania

**Michael May**  
Chief Executive Officer  
CCRM
ARM Board of Directors

Claudia Mitchell, MBA, Ph.D.
Senior VP, Product and Portfolio Strategy
Astellas Pharma

Isabelle Riviere, Ph.D.
Director, Cell Therapy and Cell Engineering Facility
Memorial Sloan Kettering Cancer Center

Sanjaya Singh, Ph.D.
VP and Global Head, Janssen BioTherapeutics, Janssen R&D
Janssen Pharmaceutical Companies of Johnson & Johnson

Donna Skerrett
Chief Medical Officer
Mesoblast

Bob Smith, MBA
SVP, Global Gene Therapy Business Pfizer

Devyn Smith, Ph.D.
Chief Strategy Officer and Head of Operations
Sigilon Therapeutics

Joe Tarnowski, Ph.D.
SVP, Cell and Gene Therapy Platform
GlaxoSmithKline

Keith Thompson
Chief Executive Officer
Cell and Gene Therapy Catapult

Arthur Tzianabos, Ph.D.
President and CEO
Homology Medicines

Gil Van Bokkelen, Ph.D.
Chairman and CEO
Athersys

Philip Vanek
GM, Cell and Gene Therapy Strategy
GE Healthcare Life Sciences

Sue Washer, MBA
President and CEO
AGTC

Jason Wertheim, M.D., Ph.D.
Edward G. Elcock Professor of Surgical Research and Associate Professor, Division of Transplantation

Donna Skerrett
Chief Medical Officer
Mesoblast

Bob Smith, MBA
SVP, Global Gene Therapy Business Pfizer
For More Information

For more information about ARM or ARM membership:

Visit: www.alliancerm.org

Contact Alyce Osborne, Director of Member Engagement:
AOsborne@alliancerm.org

Follow us on Twitter:
@alliancerm
Thank You!
<table>
<thead>
<tr>
<th>ARM’s Recent Comments, Letters, &amp; Testimony</th>
<th>Purpose</th>
<th>Recipient</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comments on ICER’s RFI “Value Assessment Methods for Single or Short-Term Transformative Therapies (SSTs)”</td>
<td>ARM finds that while there are some positive elements in ICER’s proposal, overall, the value assessment methods are inadequate to fully reflect the long-term value of these transformative therapies.</td>
<td>ICER</td>
<td>Sept 2019</td>
</tr>
<tr>
<td>Comments on the EMA guidance on quality, non-clinical and clinical requirements for investigational ATMPs</td>
<td>ARM recommends to provide additional guidance on some aspects such as non viral in vivo therapeutics and fully synthetic genome editing products, to adapt and accommodate for future improvement of RCV detection methods and in general, to ensure alignment with existing FDA requirements</td>
<td>EMA</td>
<td>July 2019</td>
</tr>
<tr>
<td>Comments on the EMA guidance on quality, non-clinical and clinical requirements for genetically modified cells</td>
<td>ARM recommends consistency in language and content with other existing guidelines, promotes international convergence of requirements and commented on some other aspects such as Replication Competent Virus or scope of the guideline</td>
<td>EMA</td>
<td>July 2019</td>
</tr>
<tr>
<td>Comments on the Proposed New Standard for Immune Effector Cell Therapy (IECT) Services</td>
<td>ARM believes that the proposed standard for the Certificate of Need Program requiring that any facility to receive both the Commission’s approval and a third-party accreditation from the FACT in order to deliver CAR-T therapies to patients in Michigan will be an onerous barrier to access.</td>
<td>MI Dept of Community Health</td>
<td>July 2019</td>
</tr>
<tr>
<td>Comments on ‘Discussion paper: Use of patient disease registries for regulatory purposes – methodological and operational considerations’</td>
<td>ARM highlighted the need for pan-European RWE infrastructures, multi-stakeholder engagement and international collaboration and made some recommendations on governance to ensure funding and sustainability of registries, for the benefits of patient market access and long-term follow-up.</td>
<td>EMA</td>
<td>June 2019</td>
</tr>
<tr>
<td>Public consultation on EMA Regulatory Science to 2025</td>
<td>ARM responded to the EMA questionnaire by identifying and commenting top priorities to address the challenges of ATMP development and foster patient access to treatment.</td>
<td>EMA</td>
<td>June 2019</td>
</tr>
<tr>
<td>Comments on the IPPS for Fiscal Year 2020</td>
<td>ARM suggests that CMS adjust its CAR T policies for the NTAP to ensure the appropriate reimbursement of these innovative therapies. ARM’s recommendations include a CAR-T specific MS-DRG and recognizing certain FDA approval designations as dispositive for newness and substantial clinical improvement</td>
<td>CMS</td>
<td>June 2019</td>
</tr>
<tr>
<td>ARM’s Recent Comments, Letters, &amp; Testimony</td>
<td>Purpose</td>
<td>Recipient</td>
<td>Date</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>----------</td>
</tr>
<tr>
<td>Comments on the Proposed Rule on the Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals</td>
<td>While ARM is supportive of the OIG’s efforts to reexamine the applicable regulatory safe harbors currently in place under the anti-kickback statute, we are concerned that the proposed change would serve to also exclude arrangements involving the application of price concessions based on value.</td>
<td>HHS OIG</td>
<td>April 2019</td>
</tr>
<tr>
<td>Comments on FDA’s ‘Rare Diseases: Common Issues in Drug Development; Draft Guidance for Industry’</td>
<td>ARM commends the FDA for the revision of the draft guidance on common issues in rare disease drug development. However, we request the Agency to consider how the guidance can leverage even more comprehensively the flexibility afforded by the FDA in the context of drug development in rare diseases.</td>
<td>FDA</td>
<td>April 2019</td>
</tr>
<tr>
<td>Comments on proposed National Coverage Decision (NCD) for Chimeric Antigen Receptor (CAR) T-cell Therapy</td>
<td>ARM asks CMS to ensure Medicare patients who can benefit from CAR T therapies are covered under the NCD, allow CAR T to be administered in certified, trained, experienced facilities and not limit access to hospitals, and certify a registry to ensure continued access to CAR T by Medicare beneficiaries.</td>
<td>CMS</td>
<td>March 2019</td>
</tr>
<tr>
<td>Comments on ICER’s RFI: Evaluation of Potentially Curative Treatments and for Translating the Results of Cost-Effectiveness Analyses into Recommendations for Value-Based Price Benchmarks</td>
<td>It is ARM’s view that traditional HTA frameworks in both U.S. and Europe are not flexible enough to accommodate potential cures and do not allow the ability to capture the full product value due to issues including: the short term time frame for assessing affordability versus the long-term timeframe for assessing value; variability in willingness to pay (and applicability of ICER threshold) based on degree of unmet medical need addressed; and the subjectivity of incorporating contextual considerations such as caregiver and societal impacts into a quantitative framework.</td>
<td>ICER</td>
<td>Feb 2019</td>
</tr>
<tr>
<td>Comments on the FDA’s &quot;Framework for a Real-World Evidence Program&quot;</td>
<td>ARM's comments encourage further clarification of the use of real world evidence (RWE) in satisfying post-approval requirements for products with RMAT designation. ARM also believes that the RWE framework document should take incorporate special considerations to address issues specific to the use of RWE for RMAT products.</td>
<td>FDA</td>
<td>Feb 2019</td>
</tr>
</tbody>
</table>
Recent ARM Successes

**RMAT Designation**
Creation of the RMAT designation to bring safe & effective therapies to market quickly

**Gene Therapy**
Inclusion of gene therapies in the RMAT designation

**RAC Reform**
NIH ended duplicative review of gene therapy trials

**Gene Editing**
Published Therapeutic Developers Statement of Principles